Power3, Methodist Hospital Partner on Biomarker-Based Blood Tests for Neurodegenerative Disease
Power3 Medical Products and the Methodist Hospital Research Institute have partnered to search for protein biomarkers and develop a suite of tests for the diagnosis of neurodegenerative disease, Power3 said this week.
In collaboration with Stan Appel, chair of neurology at Methodist Neurological Institute, Power3 has completed clinical validation by testing serum proteins from more than 600 patients with Lou Gehrig's, Alzheimer's, and Parkinson's disease.
Power3 said that it continues to evaluate serum from patients and plans to publish results from the study later this year.
GE Healthcare Revenues Increase 12 Percent in Q2
GE Healthcare's revenues during the second quarter of 2005 increased 12 percent year over year, to $3.8 billion, GE reported last week.
The business unit, which incorporated Amersham Biosciences in April of last year, contributed 9 percent to GE's overall quarterly revenues of $41.6 billion, similar to the same period in 2004. GE's total revenues were up 13 percent over last year's $36.8 billion during the second quarter.
Orders for the healthcare business unit grew 11 percent over the second quarter of 2004, to $3.9 billion, $2.5 billion of which came from equipment orders.
Healthcare had $672 million in profits, up 15 percent from $584 million during the same period last year.
GE's total earnings amounted to $4.6 billion, up 24 percent from $3.8 billion in the second quarter of last year. Earnings per share were $.44, up 22 percent over last year's $.36 during the same period.
As of June 30, GE had $146 billion in cash and marketable securities.
Bank Upgrades Waters Stock, Expects 'Positive' Q2 Results
Merrill Lynch upgraded Waters stock to "buy" from "neutral" this week and said it expects the company to report positive second-quarter results on July 26.
Broad Institute 'Likely' to Start Occupying New Cambridge Digs in April
The Broad Institute's new Cambridge home will be completed in January 2006 and the institute is "likely" to occupy the space in April, according to an institute spokeswoman.
"That's our goal," Michelle Nhuch told GenomeWeb News this week. The Broad's landlord, Boston Properties, last year said the building will be complete and available for occupancy during the first quarter 2006, which spans January-March.
The 230,000-square-foot facility is located at 7 Cambridge Center and sits near the Whitehead Institute for Biomedical Research and the East Campus of MIT. The Broad is a partnership between MIT, the Whitehead, and Harvard, and people close to the matter said that the site was chosen for its proximity to these labs.
Cambridge Center is located at the center of Kendall Square, directly across the Charles River from downtown Boston. The deal is believed to be the largest lab-lease agreement in Cambridge since Novartis decided to locate its US research headquarters in the area in 2002.
The Broad building will be 60 percent to 70 percent lab space and 30 percent to 40 percent office space. And although news reports in real-estate trade publications have said that the Broad will occupy 100 percent of the space, Nhuch today said that a restaurant will occupy the first floor of the building.
Created in 2003, the Broad chose the 7 Cambridge Center address over an existing space located at 675 W. Kendall St. that had been leased by Vertex Pharmaceuticals. Last spring, Vertex tried and failed to entice the institute to sublet the property which was competing against the 7 Cambridge Center address for Broad's affection at which point its owner, New Hampshire-based Lyme Properties, sold it to a realty trust at the end of May, according to a Lyme official.
The official noted that the Broad recently leased a 50,000-square-foot facility from its inventory located on 320 Bent St., in Cambridge. The institute currently occupies three Cambridge addresses: 320 Charles Street, 320 Bent Street, and One Kendall Square, Building 300.
Max Planck's Biophysical Chemistry Dept. Installs Formulatrix Technology
Formulatrix this week said that the Max Planck Institute's department of biophysical chemistry has installed the company's Rock Maker and Rock Imager for protein crystallization automation.
Financial details of the deal were not disclosed.
Rosetta Biosoftware, GeneGo to Make Their Platforms Interoperable
Rosetta Biosoftware and GeneGo intend to establish interoperability between Rosetta's Resolver system and GeneGo's MetaCore system, the companies said this week.
The goal is to enable mutual scientists to exchange data between the MetaCore and Resolver systems for gene-expression and pathway-analysis research.
Financial terms of the alliance were not disclosed.
Ninth Journal Will Submit Interaction Data to BIND Ahead of Publication
The Journal of Biomolecular Screening will submit molecular interaction data to the Biomolecular Interaction Network Database prior to publication, becoming the ninth journal to take this step, the Blueprint Initiative, which maintains BIND, said last week.
Under the agreement with the journal's publisher, SAGE Publications, data from pre-publication manuscripts will be submitted to BIND and BIND record identifiers will be published in the final articles.
The Journal of Biomolecular Screening is the ninth journal to require pre-publication data to be submitted to BIND. The others include Science, Nature Cell Biology, and Immunology.
Welsh University Buys $540K Worth of Caliper Equipment for Aging Research
The University of Aberystwyth in Wales has recently bought £450,000 ($539,000) worth of equipment from Caliper Life Sciences to spruce up its Institute for Biological Sciences, a Caliper official said this week.
Simon Minchin, who heads the UK and Ireland sales team for the Hopkinton, Mass.-based life sciences company, said the school will use Caliper's SciClone i1000 high volume liquid-handling station to study yeast-based biogerontology.
Minchin spoke with ProteoMonitor's sister publication GenomeWeb News at the BioScience 2005 conference, held here this week.
The SciClone i1000 distributes samples to 96- and 384-well microplates. Aberystwyth's IBS has competencies in proteomics, metabolomics, bioinformatics, and microbiology, according to its website.